2010•Clinical Medicine Insights TherapeuticsOpen access

Vardenafil in Erectile Dysfunction: The Evidence of Its Therapeutic Value

Kevin R. Rice, Robert C. Dean

Abstract

Erectile dysfunction (ED) is a condition that affects approximately 18 million American men. Phosphodiesterase-5 inhibitors (PDE5i's) have revolutionized the treatment of erectile dysfunction by providing the first highly-effective oral medication. Vardenafil is one of 3 PDE5i's commercially available for the treatment of ED in the United States. It has demonstrated therapeutic efficacy in the management of uncomplicated ED as well as more refractory cases associated with diabetes and surgery for prostate cancer. The physiology, pharmacokinetics, pharmacodynamics, and primary literature evaluating vardenafil are reviewed.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Vardenafil, Erectile dysfunction, Medicine, cGMP-specific phosphodiesterase type 5, Prostate cancer, Sildenafil, Pharmacodynamics, Diabetes mellitus